A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/18/2004	US20040229947 Method of treating hyperactive bladder using phenoxyacetic acid derivatives
11/18/2004	US20040229946 Antidiabetic agents
11/18/2004	US20040229945 use in inhibiting angiogenesis in a mammal
11/18/2004	US20040229944 Apoptosis inducer and method of screening for a substance inhibiting acylated homoserine lactone
11/18/2004	US20040229943 Analeptic and drug combinations
11/18/2004	US20040229942 Analeptic and antidepressant combinations
11/18/2004	US20040229941 Analeptic and antidepressant combinations
11/18/2004	US20040229940 Analeptic and antidepressant combinations
11/18/2004	US20040229939 sublingual delivery of tetrahydrocannabinol and suitable for tableting, comprising tetrahydrocannabinol, ethanol, a buffer, an antioxidant, a water-soluble excipient, a detergent, a sweetener, and a glidant, to treat or to ameliorate emesis, anorexia, or chronic or AIDS-related wasting syndrome
11/18/2004	US20040229938 Reacting dihydroartemisin or dihydroartemistene with an appropriate optionally substituted 1, 2 or 1, 3 or 1, 4 glycol under acidic conditions such as borontrifluoride etherate followed by additional functionallization of the resulting dimer; anti-malarial and anti-leishmanial
11/18/2004	US20040229937 diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
11/18/2004	US20040229936 sesquiterpene lactones having a gamma -lactone fused with a 10-membered ring, an 8-membered ring that is further fused with a 4-membered ring, a 7-membered ring that is further fused with a 5-membered ring, or a 6-membered ring that is further fused with a 6-membered ring.
11/18/2004	US20040229934 use of an angiotensin-converting enzyme inhibitor, ramipril, to reduce the decline of beta -cell function, increase islet blood flow, lower aldosterone secretion, lower renal potassium wasting, increase pancreatic beta -cell perfusion, reduce insulin resistance in skeletal muscles,
11/18/2004	US20040229933 Treatment of hypertension
11/18/2004	US20040229932 osteoarthritis; little to no intrinsic estrogenicity; antagonizes the effects of 17 beta -estradiol with minimal uterine stimulation; bone loss inhibitor
11/18/2004	US20040229930 treatment of protein kinase related disorders.
11/18/2004	US20040229928 Method for regulation of microvascular tone
11/18/2004	US20040229927 Imidazole derivatives for treatment of allergic and hyperproliferative disorders
11/18/2004	US20040229924 Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors
11/18/2004	US20040229923 Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying
11/18/2004	US20040229922 Sulfur compounds such as phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate, used for prevention of viral diseases and replication
11/18/2004	US20040229921 Methods and compositions for treating hypertension, angina, and other disorders using optically pure (-) amlodipine
11/18/2004	US20040229920 Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
11/18/2004	US20040229919 As diuretic agent, as an agent for preventing heart or heart tissue damages caused by metabolic or ionic abnormalities associated with ischemia, in the treatment of thrombosis, angina pectoris, asthma, hypertension, nephroedema, pulmonary edema, primary and secondary aldosteronism, Bartter's syndrome
11/18/2004	US20040229917 Imidazole derivatives
11/18/2004	US20040229913 Administering 3.0 mg to 10 mg of 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient
11/18/2004	US20040229911 Therapy of disorder or condition that can be treated by altering circadian rhythms in a mammal, comprising administering: NOS inhibiting compound, or pharmaceutically acceptable salt thereof; andNK-1 receptor antagonist or a pharmaceutically acceptable salt thereof
11/18/2004	US20040229910 Therapeutic compounds
11/18/2004	US20040229909 Antiviral agent
11/18/2004	US20040229908 Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
11/18/2004	US20040229907 2-Aminoquinolinecarboxamides: neurokinin receptor ligands
11/18/2004	US20040229906 Dichlorinated heterocyclic compounds and methods of synthesis
11/18/2004	US20040229903 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure
11/18/2004	US20040229901 For therapy of cardiac disease and/or renal failure
11/18/2004	US20040229898 Administering compounds such as 6-chloro-2-methoxy-acridin-9-yl)-(3-{4-[3-(6-chloro-2-methoxy-acridin-9-ylamino)-propyl]-piperazin-1-yl}-propyl)-amine for clearing malformed proteins and by an ability to cross a blood brain barrier
11/18/2004	US20040229897 Aid in cytokine biosynthesis
11/18/2004	US20040229896 Stable pharmaceutical compositions of desloratadine
11/18/2004	US20040229895 Tetracyclic benzamide derivatives and methods of use thereof
11/18/2004	US20040229893 Substituted benzothiazole amide derivatives
11/18/2004	US20040229892 HIV integrase inhibitors
11/18/2004	US20040229888 Administering xanthine derivatives for therapy of brain ischemia
11/18/2004	US20040229887 Novel imidazopyrimidinyl and imidazopyri dinyl derivatives
11/18/2004	US20040229886 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
11/18/2004	US20040229885 Xanthine phosphodiesterase V inhibitors
11/18/2004	US20040229884 Sodium channel blockers
11/18/2004	US20040229883 Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; therapy of metabolic, feeding, and sexual disorders including obesity
11/18/2004	US20040229882 dipeptide or tripeptide MC-1R and MC-4R agonists
11/18/2004	US20040229881 Methods of use of antimicrobial compounds against pathogenic mycoplasma bacteria
11/18/2004	US20040229880 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
11/18/2004	US20040229879 CRF receptor antagonists and methods relating thereto
11/18/2004	US20040229876 Quinoline derivatives and quinazoline derivatives having azolyl group
11/18/2004	US20040229875 Administering compounds such as 4-(2-Amino-5-phenyl-pyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid dimethylamide for therapy of transplant rejection, melanoma, or a cancer selected from colon, breast, lung, kidney, ovary, pancreas, CNS, or cancer of the gastric tract
11/18/2004	US20040229873 Treatment of neurodegenerative conditions
11/18/2004	US20040229872 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity
11/18/2004	US20040229871 Nitrogen compounds such as 2-(5-(4-Fluoro-benzyloxy)-1,3-dioxo -1,3-dihydro-isoindol-2-yl)-acetamide, used for prophylaxis of Alzheimer's disease; amine oxidase inhibitors
11/18/2004	US20040229870 Certain alkylene diamine-substituted heterocycles
11/18/2004	US20040229867 Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (R) 2,3-benzodiazepine
11/18/2004	US20040229866 Administering to the individual an effective amount of (S)-tofisopam, substantially isolated from the corresponding (R)-enantiomer of tofisopam, or a pharmaceutically-acceptable salt thereof
11/18/2004	US20040229865 Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
11/18/2004	US20040229864 An aromatic or heteroaromatic ring attached sulfone compound having a nitrogen containing hetero-mono, bi or tricyclic ring useful for treating sleep disorder and depression
11/18/2004	US20040229863 Administering 4-amino-azepan-3-one compound for inhibiting cathepsin S
11/18/2004	US20040229861 CGRP receptor antagonists
11/18/2004	US20040229860 For enhancing bone formation; for therapy of diseases or disorders associated with abnormal bone or mineral homeostasis
11/18/2004	US20040229859 Beta-amino acid compounds as integrin antagonists
11/18/2004	US20040229857 Neurotherapeutic composition and method
11/18/2004	US20040229856 Administering an effective dose of 17- beta estradiol or a derivative thereof
11/18/2004	US20040229855 Administering glucocorticoid receptor antagonist effective to ameliorate the symptoms of the postpartum psychosis, with the proviso that the first psychotic symptoms arise within nine months of childbirth, that the patient has never suffered any psychotic condition not triggered by childbirth
11/18/2004	US20040229854 Administering to a patient in need thereof an effective amount of a pharmaceutical formulation in the form of an immediate-release peroral dosage unit, comprising tibolone, wherein the pharmaceutical formulation has a bioavailability, in vivo, of 3 alpha -OH tibolone
11/18/2004	US20040229853 Subjecting compound such as 3,3-ethylenedioxy-5(10)-epoxyestr-9(11)-ene-17-one to an alkylation reaction with an organocuprate derivative, reacting with deprotecting agent, aromatization to obtain compound such as 17-alpha-fluoro-11-beta-(4-(2-(1-piperidinyl)ethoxy)phenyl)estra-4,9-dien-3-one
11/18/2004	US20040229852 Pharmaceutical composition for enhancing immunity, and extract of Poria
11/18/2004	US20040229850 Method and kit for regulation of microvascular tone
11/18/2004	US20040229849 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
11/18/2004	US20040229848 For therapy of non-insulin dependent diabetes
11/18/2004	US20040229847 Pyridinone and pyridinethione derivatives having hiv inhibiting properties
11/18/2004	US20040229846 P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions
11/18/2004	US20040229845 Modified PSMA ligands and uses related thereto
11/18/2004	US20040229844 Administering to the patient nicotinic acid or a pharmaceutically acceptable salt or solvate thereof, or another nicotinic acid receptor agonist and a DP receptor antagonist in amounts that are effective for treating atherosclerosis in the absence of substantial flushing
11/18/2004	US20040229843 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
11/18/2004	US20040229842 Use of lipid conjugates in the treatment of diseases
11/18/2004	US20040229841 Method for treating cancer using camptothecin derivatives and 5-fluorouracil
11/18/2004	US20040229839 Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
11/18/2004	US20040229837 Identifying a subject suffering from or being at risk for developing a neurodegenerative disease, administering to the subject an effective amount of an agonist of an A2A-adenosine receptor
11/18/2004	US20040229835 Immunostimulatory nucleic acid molecules
11/18/2004	US20040229833 Therapeutic use of cis-element decays in vivo
11/18/2004	US20040229831 Compositions and methods for non-parenteral delivery of oligonucleotides
11/18/2004	US20040229829 Enzyme inhibitors for metabolic redirection
11/18/2004	US20040229828 Administering a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide at least 10 nucleotides in length
11/18/2004	US20040229826 Dose-dense & sequential adjuvant cancer chemotherapy
11/18/2004	US20040229824 Methods for using specific saccharides for treating Alzheimer's disease and other amyloidoses
11/18/2004	US20040229823 For use in therapy of growth metabolic disorders
11/18/2004	US20040229822 Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof
11/18/2004	US20040229819 Hemiasterlin derivatives and uses thereof
11/18/2004	US20040229817 Inhibitors of Hepatitis C virus, compositions and treatments using the same
11/18/2004	US20040229813 Pharmaceutical preparations for treatments of diseases and disorders of the breast
11/18/2004	US20040229807 employing combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin
11/18/2004	US20040229803 Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
11/18/2004	US20040229802 Methods and compositions for treating ocular disease
11/18/2004	US20040229801 Provides anti-fungal compounds, including peptides and peptidomimetics having anti-fungal activity alone, and in combination with other agents that have anti-fungal activity, and methods of using the compounds for killing or inhibit growth of yeast, mold, slimes
11/18/2004	US20040229800 Stimulating nerve cell growth in a subject by administering a bastadin compound or its analogs
11/18/2004	US20040229796 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto

1 ... 4887 4888 4889 4890 4891 4892 4893 4894 4895 4896 4897 4898 4899 4900 4901 4902 4903 4904 4905 4906 4907 ... 7860